Thanneer Malai Perumal, Arnaud Wolfer, Florian Lipsmeier, Michael Lindemann, Foteini Orfaniotou, Simone Rey-Riek, Irma T. Kurniawan, David Watson, Mercè Boada, Kirsten I. Taylor

1. Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland, 2. Global Product Development Medical Affairs, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland, 3. Zurich Center for Neuroeconomics, Department of Economics, University of Zurich, Switzerland, 4. Alzheimer's Research and Treatment Center, Wellington, FL, USA, 5. Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya, Barcelona, Spain, 6. Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Introduction

Digital assessment suite

Objectives

Study design

Participants

Demographics

Results I

Results II

Results III

Results IV

Results V

Conclusions

Acknowledgements >

The promise of remote monitoring of cognition in AD

- Subtle cognitive changes emerge years prior to clinical diagnosis of AD. This window offers a promising
 opportunity for preventing decline.
- Frequent remote monitoring of cognition enables the possibility of capturing these subtle changes in cognition in a an ecologically valid setting (e.g. recall over days)
 - More frequent measurement may also increase signal-to-noise ratio of remote monitoring outcomes to generate more reliable and ultimately valid measures of cognitive performance and changes over time
- Cognitive domains relevant for remote monitoring in the continuum of preclinical to eAD include:
 - Episodic long-term memory (declining first in the preclinical phase)
 - Learning, semantic memory, and executive functioning (affected in prodromal and eAD)
- A comprehensive battery of cognitive tests enables generation of profiles of cognitive impairment across domains. Examples of their use include to:
 - Differentiate dementia syndromes
 - Enable quantification of contribution of non-AD pathology to syndrome
 - Quantify impairments associated with vascular dementia

AD, Alzheimer's disease; eAD, early Alzheimer's disease.

Thanneer Malai Perumal¹, Arnaud Wolfer¹, Florian Lipsmeier¹, Michael Lindemann¹, Foteini Orfaniotou², Simone Rey-Riek², Irma T. Kurniawan^{1,3}, David Watson⁴, Mercè Boada^{5,6}, Kirsten I. Taylor¹

Introduction

Digital Assessment Suite

Objectives

Study design

Participants

Demographics

Results I

Results II

Results III

Results IV

Results V

Conclusions

Acknowledgements >

Remote assessments of cognition and functioning in daily life (with an expected daily burden ~10 min/day^a)

				ACTIVE TASKS				
Episodic memory	Executive functioning	Logical memory & conceptual fluency	Semantic memory	Visuospatial working memory	Psychomotor speed, attention	Gait and balance	Fine motor	Psychomotor speed, language
Gallery game	Tilt task	Story time	Object features	Find the egg	IPS	30-sec walk	Speeded tapping	Fairy-tale
SURVEYS (provisioned smartphones)			PASSIVE MONITORING (in participant's smartphone)					
Sleep quality	Mood	Social behavior	Orientation	Location & activity patterns	Gait and balance	Ambient noise	App usage	Screen usage

^aActual burden shown in results AD, Alzheimer's disease; GPS, Global Positioning System; IPS, information processing speed.

Thanneer Malai Perumal¹, Arnaud Wolfer¹, Florian Lipsmeier¹, Michael Lindemann¹, Foteini Orfaniotou², Simone Rey-Riek², Irma T. Kurniawan^{1,3}, David Watson⁴, Mercè Boada^{5,6}, Kirsten I. Taylor¹

Introduction

Digital assessment suite

Objectives

Study design

Participants

Demographics

Results I

Results II

Results III

Results IV

Results V

Conclusions

Acknowledgements >



Primary objective:

 To evaluate feasibility and adherence to smartphone-based remote self-assessments, including user experience in participants with eAD, SCD, and healthy controls




Secondary and exploratory objectives:

- To explore associations between sensor data on cognition, function, and behavior collected using smartphones and in-clinic assessments including neuropsychological tests
- To explore whether sensor data collected using smartphones are different between participants with and without cognitive impairment
- To explore associations between the clinical assessments,
 smartphone-based sensor data and the brain imaging read-out

eAD, early Alzheimer's disease; SCD, subjective cognitive decline

Thanneer Malai Perumal¹, Arnaud Wolfer¹, Florian Lipsmeier¹, Michael Lindemann¹, Foteini Orfaniotou², Simone Rey-Riek², Irma T. Kurniawan^{1,3}, David Watson⁴, Mercè Boada^{5,6}, Kirsten I. Taylor¹



Thanneer Malai Perumal¹, Arnaud Wolfer¹, Florian Lipsmeier¹, Michael Lindemann¹, Foteini Orfaniotou², Simone Rey-Riek², Irma T. Kurniawan^{1,3}, David Watson⁴, Mercè Boada^{5,6}, Kirsten I. Taylor¹

Introduction

Digital assessment suite

Objectives

Study design

Participants

Demographics

Results I

Results II

Results III

Results IV

Results V

Conclusions

Acknowledgements >

Key inclusion and exclusion criteria

	Healthy control	Subjective cognitive decline	Early Alzheimer's disease		
Age	65 years or above				
Diagnosis	Clinical neuropsychological testing as defined by a performance not worse than one standard deviation (1 SD) below the mean , based on normative data	-	NIA-AA criteria for MCI due to AD or probable AD		
CCI (on first 12 questions)	< 16	≥ 16	-		
MMSE	≥ 29 (with high-school graduation) ≥ 28 (without high-school graduation)	≥ 27 (with high-school graduation) ≥ 26 (without high-school graduation)	≥ 24 (with high-school graduation) ≥ 23 (without high-school graduation)		
CDR	0	0	0.5		
Amyloid beta pathology (PET)	Negative	Negative (Not more than 30 participants) Positive (20 to 30 participants)	Positive		
Other inclusion	 Previous experience with smartphone or tablet Fluency in the language of the tests used at the Adequate visual and auditory acuity 				
Key exclusion	 History or known presence of any significant neurological disorders History or known presence of any significant psychiatric disorders Current active clinically significant anxiety or depressive disorder 				

AD, Alzheimer's disease; CCI, Cognitive Change Index; CDR, Clinical dementia rating; eAD, early Alzheimer's disease; MMSE, Mini-Mental State Examination; NIA-AA, National Institute on Aging and Alzheimer's Association; PET, positron emission tomography; SD, standard deviation.

Thanneer Malai Perumal¹, Arnaud Wolfer¹, Florian Lipsmeier¹, Michael Lindemann¹, Foteini Orfaniotou², Simone Rey-Riek², Irma T. Kurniawan^{1,3}, David Watson⁴, Mercè Boada^{5,6}, Kirsten I. Taylor¹

Introduction

Digital assessment suite

Objectives

Study design

Participants

Demographics

Results I

Results II

Results III

Results IV

Results V

Conclusions

Acknowledgements >

Demographics

	нс	SCD negative	SCD positive	eAD	Total
N	32	31	30	30	123
Age (Median) [range]	68.5 [65 - 83]	70 [65 - 89]	72 [65 - 82]	74.5 [65 - 83]	71 [65 - 89]
Gender (M:F)	20:12	17:14	16:14	18:12	71:52
Ethnicity (Hispanic:Non Hispanic)	14:18	6:25	10:20	8:22	38:85
Race (Asian:African-American:White)	0:3:29	1:2:28	0:0:30	0:1:29	1:6:116
Language (English:Spanish)	17:15	17:14	14:16	16:14	64:59
Years of education [range]	12 [17 - 8]	15 [17 - 8]	14 [17 - 8]	13 [17 - 8]	13 [17 - 8]

Thanneer Malai Perumal¹, Arnaud Wolfer¹, Florian Lipsmeier¹, Michael Lindemann¹, Foteini Orfaniotou², Simone Rey-Riek², Irma T. Kurniawan^{1,3}, David Watson⁴, Mercè Boada^{5,6}, Kirsten I. Taylor¹

SCD-negative

Introduction Digital assessment suite **Objectives** Study design **Participants Demographics** Results I Results II Results III Results IV Results V Conclusions

Acknowledgements >

20

15

10

5

HC

97.5% feasibility (120 out of 123 participants successfully completed the study) Study completion by group 35 30 25

Enrolled (n)

Others (n)

Completed (n)

Early withdrawal (n)

	Enrolled	Completed	Early withdrawal	Others
Total, n	123	120	2	1

SCD-positive

eAD

Thanneer Malai Perumal¹, Arnaud Wolfer¹, Florian Lipsmeier¹, Michael Lindemann¹, Foteini Orfaniotou², Simone Rey-Riek², Irma T. Kurniawan^{1,3}, David Watson⁴, Mercè Boada^{5,6}, Kirsten I. Taylor¹

Introduction

Digital assessment suite

Objectives

Study design

Participants

Demographics

Results

Results II

Results III

Results IV


Results V

Conclusions

Acknowledgements >

96.4% median adherence observed across all cohorts within the 28-day remote monitoring period

- Overall adherence is the proportion of remote study days on which participants completed at least one planned task relative to the number of remote study days with planned active testing (i.e. 28 days)
- Good adherence was observed, even in eAD participants
- Adherence is comparable across all cohorts




Thanneer Malai Perumal¹, Arnaud Wolfer¹, Florian Lipsmeier¹, Michael Lindemann¹, Foteini Orfaniotou², Simone Rey-Riek², Irma T. Kurniawan^{1,3}, David Watson⁴, Mercè Boada^{5,6}, Kirsten I. Taylor¹

Introduction Digital assessment suite **Objectives** Study design **Participants Demographics** Results I Results II Results III Results IV Results V Conclusions

Acknowledgements >

85.8% rated their user experience as good or very good

- All participants provided their feedback on app usability by participating in a user experience survey at the end of study
- ~86% of respondents rated their experience as good or very good in using the study smartphone and the assessment app



Thanneer Malai Perumal¹, Arnaud Wolfer¹, Florian Lipsmeier¹, Michael Lindemann¹, Foteini Orfaniotou², Simone Rey-Riek², Irma T. Kurniawan^{1,3}, David Watson⁴, Mercè Boada^{5,6}, Kirsten I. Taylor¹

Introduction

Digital assessment suite

Objectives

Study design

Participants

Demographics

Results I

Results II

Results III


Results IV

Results V

Conclusions

Acknowledgements >

On average, participants spent 10.9 minutes a day performing the remote assessments; the majority rated their perceived burden to be acceptable



• Healthy controls spent less time (9.79+/-3 minutes) in comparison with eAD (12.5+/-3.11 minutes) who took more time to complete the schedule of assessments


Thanneer Malai Perumal¹, Arnaud Wolfer¹, Florian Lipsmeier¹, Michael Lindemann¹, Foteini Orfaniotou², Simone Rey-Riek², Irma T. Kurniawan^{1,3}, David Watson⁴, Mercè Boada^{5,6}, Kirsten I. Taylor¹



Acknowledgements >

More than 89% of the participants agreed that the task instructions were clear and easy to follow

- 107 participants rated ≥ 5 (i.e.
 6 being "I completely agree")
 signifying the task instructions
 were clear and easy to read
- No significant differences observed across different cohorts



Thanneer Malai Perumal¹, Arnaud Wolfer¹, Florian Lipsmeier¹, Michael Lindemann¹, Foteini Orfaniotou², Simone Rey-Riek², Irma T. Kurniawan^{1,3}, David Watson⁴, Mercè Boada^{5,6}, Kirsten I. Taylor¹

manneer waar erumar, Amada woner,	Thomas Elpander , Michael Elitaemann, Fotenii Orianiotou, Olimone Ney-Nek, Ilma F. Namiawan F, David Watson, Merce Boada F, Niisten I. Taylor
Introduction	
Digital assessment suite	Remote monitoring of cognition holds promise to provide denser, more ecologically
Objectives	valid measures of cognitive functioning (e.g. recall over days), with a very broad reach
Study design	
Participants	Feasibility, acceptance, and adherence are fundamental metrics in the development of a remote monitoring solution for the AD continuum
Demographics	a remote monitoring solution for the AD continuum
Results I	Primary results from this proof-of-concept study show excellent feasibility, acceptable
Results II	adherence, and good user experience for the suite of digital assessments presented here in healthy volunteers, subjective cognitive decline, and early AD individuals
Results III	There in fleating volunteers, subjective cognitive decline, and early AD individuals
Results IV	Further analysis on the psychometric properties of the individual tasks will be
Results V	presented later in the year
Conclusions	
	AD. Alzheimer's disease.

Acknowledgements >

Thanneer Malai Perumal¹, Arnaud Wolfer¹, Florian Lipsmeier¹, Michael Lindemann¹, Foteini Orfaniotou², Simone Rey-Riek², Irma T. Kurniawan^{1,3}, David Watson⁴, Mercè Boada^{5,6}, Kirsten I. Taylor¹



Study design

Objectives

Participants

Demographics

Results I

Results II

Results III


Results IV

Results V

Conclusions

Acknowledgements >

Acknowledgements



We would like to acknowledge the contributions by Mr. Wael Abouelkheir, Dr. Beijue Shi, Dr. Niels Hagenbuch, Ms. Goullou Keita, Ms. Emma Poon, and Mr. Miguel Veloso.

This study was sponsored by F. Hoffmann-La Roche Ltd., Basel, Switzerland.

Editorial support for the development of this presentation was provided by Jack O'Neill of Nucleus Global, funded by F. Hoffmann-La Roche Ltd.

